Citadel Advisors
HZNP

Citadel Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Citadel Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,149,825
Closed -$480M – 15761
2023
Q3 		$480M Sell
4,149,825
-313,276
-7% -$33.7M 0.1% 104
2023
Q2 		$459M Buy
4,463,101
+485,092
+12% +$51.2M 0.09% 104
2023
Q1 		$434M Buy
3,978,009
+2,712,069
+214% +$300M 0.1% 116
2022
Q4 		$144M Sell
1,265,940
-1,463,094
-54% -$122M 0.03% 478
2022
Q3 		$169M Buy
2,729,034
+2,275,125
+501% +$159M 0.04% 375
2022
Q2 		$36.2M Buy
453,909
+278,543
+159% +$26.4M 0.01% 1293
2022
Q1 		$18.4M Sell
175,366
-1,039,961
-86% -$101M ﹤0.01% 2073
2021
Q4 		$131M Sell
1,215,327
-593,822
-33% -$64.8M 0.03% 522
2021
Q3 		$198M Buy
1,809,149
+76,786
+4% +$7.97M 0.04% 340
2021
Q2 		$162M Buy
1,732,363
+774,230
+81% +$71.2M 0.04% 416
2021
Q1 		$88.2M Buy
958,133
+319,243
+50% +$26.9M 0.02% 653
2020
Q4 		$46.7M Sell
638,890
-646,067
-50% -$48M 0.01% 996
2020
Q3 		$99.8M Sell
1,284,957
-2,397,293
-65% -$165M 0.03% 466
2020
Q2 		$205M Buy
3,682,250
+84,598
+2% +$3.62M 0.07% 174
2020
Q1 		$107M Buy
3,597,652
+2,230,627
+163% +$75.5M 0.05% 314
2019
Q4 		$49.5M Buy
1,367,025
+867,360
+174% +$26.6M 0.02% 776
2019
Q3 		$13.6M Sell
499,665
-681,806
-58% -$17.6M 0.01% 1878
2019
Q2 		$28.4M Buy
1,181,471
+805,961
+215% +$20.4M 0.01% 1114
2019
Q1 		$9.93M Buy
375,510
+266,496
+244% +$6.31M ﹤0.01% 2087
2018
Q4 		$2.13M Sell
109,014
-98,705
-48% -$1.93M ﹤0.01% 4045
2018
Q3 		$4.07M Buy
207,719
+192,926
+1,304% +$3.67M ﹤0.01% 3266
2018
Q2 		$245K Sell
14,793
-174,589
-92% -$2.66M ﹤0.01% 7556
2018
Q1 		$2.69M Sell
189,382
-465,051
-71% -$6.87M ﹤0.01% 3292
2017
Q4 		$9.55M Sell
654,433
-993,024
-60% -$13.9M 0.01% 1783
2017
Q3 		$20.9M Sell
1,647,457
-2,325,115
-59% -$29.6M 0.02% 1042
2017
Q2 		$47.2M Buy
3,972,572
+3,691,671
+1,314% +$45.9M 0.04% 529
2017
Q1 		$4.15M Sell
280,901
-114,008
-29% -$1.85M ﹤0.01% 2236
2016
Q4 		$6.39M Buy
394,909
+82,843
+27% +$1.5M 0.01% 1742
2016
Q3 		$5.66M Buy
312,066
+224,002
+254% +$4.38M 0.01% 1856
2016
Q2 		$1.45M Sell
88,064
-2,084,814
-96% -$33.7M ﹤0.01% 3104
2016
Q1 		$36M Buy
2,172,878
+1,660,162
+324% +$29M 0.05% 431
2015
Q4 		$11.1M Buy
512,716
+252,973
+97% +$4.92M 0.01% 1193
2015
Q3 		$5.15M Sell
259,743
-1,530,444
-85% -$48.4M ﹤0.01% 1922
2015
Q2 		$62.2M Buy
1,790,187
+1,129,494
+171% +$34.5M 0.05% 412
2015
Q1 		$17.2M Buy
660,693
+595,037
+906% +$10.9M 0.02% 1069
2014
Q4 		$846K Sell
65,656
-113,185
-63% -$1.42M ﹤0.01% 3973
2014
Q3 		$2.2M Buy
+178,841
New +$2.08M ﹤0.01% 2754
2014
Q2 		– Sell
-74,632
Closed -$1.07M – 8490
2014
Q1 		$1.13M Sell
74,632
-19,529
-21% -$221K ﹤0.01% 3279
2013
Q4 		$718K Buy
94,161
+24,520
+35% +$132K ﹤0.01% 3579
2013
Q3 		$236K Buy
69,641
+10,869
+18% +$28.7K ﹤0.01% 4607
2013
Q2 		$145K Buy
+58,772
New +$141K ﹤0.01% 4935

Other funds holding HZNP

IA
IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return
VWA
Valued Wealth Advisors Holladay, Utah $247M AUM 21.93% 1-Year Est. Return
FSWA
Financial Synergies Wealth Advisors Houston, Texas $1.18B AUM 31.41% 1-Year Est. Return
BCMLT
Beacon Capital Management LLC (Tennessee) Franklin, Tennessee $567M AUM 16.01% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citadel Advisors's HZNP Position: Q4 2023 in Review

Citadel Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2023, closing a stake of 4,149,825 shares — an estimated $480M sold.

Citadel Advisors first reported a position in HZNP in Q2 2013 and held it in 41 quarters. The position peaked at $480M in Q3 2023. 6 funds tracked by Wall St. Rank hold HZNP as of Q4 2023.

  • Citadel Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Citadel Advisors sold 4,149,825 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2023, an estimated $480M.
  • Citadel Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2013 and held it in 41 quarters.
  • Citadel Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $480M in Q3 2023.
  • 6 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2023.

Based on Citadel Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.